JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

166.57 -2.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

164.44

Máximo

169.65

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+16.2% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.2B

9.2B

Abertura anterior

169.38

Fecho anterior

166.57

Sentimento de Notícias

By Acuity

25%

75%

70 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de abr. de 2026, 23:15 UTC

Notícias Principais

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 de abr. de 2026, 23:08 UTC

Ganhos
Grandes Movimentos do Mercado

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 de abr. de 2026, 23:58 UTC

Ganhos

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 de abr. de 2026, 23:58 UTC

Ganhos

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 de abr. de 2026, 23:56 UTC

Ganhos

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 de abr. de 2026, 23:56 UTC

Ganhos

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 de abr. de 2026, 23:42 UTC

Conversa de Mercado

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 de abr. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 de abr. de 2026, 23:08 UTC

Conversa de Mercado

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 de abr. de 2026, 23:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de abr. de 2026, 23:02 UTC

Conversa de Mercado

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 de abr. de 2026, 22:42 UTC

Conversa de Mercado

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 de abr. de 2026, 22:10 UTC

Ganhos

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 de abr. de 2026, 21:56 UTC

Ganhos

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 de abr. de 2026, 21:55 UTC

Ganhos

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 de abr. de 2026, 21:55 UTC

Ganhos

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 de abr. de 2026, 21:44 UTC

Ganhos

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 de abr. de 2026, 21:43 UTC

Ganhos

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 de abr. de 2026, 21:41 UTC

Ganhos

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 de abr. de 2026, 21:41 UTC

Ganhos

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de abr. de 2026, 20:39 UTC

Ganhos

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

16.2% parte superior

Previsão para 12 meses

Média 197.3 USD  16.2%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

70 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat